AR045470A1 - Derivados de acido fenoxiacetico - Google Patents

Derivados de acido fenoxiacetico

Info

Publication number
AR045470A1
AR045470A1 ARP040102990A ARP040102990A AR045470A1 AR 045470 A1 AR045470 A1 AR 045470A1 AR P040102990 A ARP040102990 A AR P040102990A AR P040102990 A ARP040102990 A AR P040102990A AR 045470 A1 AR045470 A1 AR 045470A1
Authority
AR
Argentina
Prior art keywords
alkyl
halogen
cycloalkyl
optionally substituted
substituents independently
Prior art date
Application number
ARP040102990A
Other languages
English (en)
Inventor
Roger Victor Bonnert
Anthony Cook
Timothy Luker
Mohammed Rukhsana
Stephen Thom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0302281A external-priority patent/SE0302281D0/xx
Priority claimed from GB0412448A external-priority patent/GB0412448D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR045470A1 publication Critical patent/AR045470A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/38—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. nitrodiphenyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

La presente se refiere a su utilización como compuestos farmacéuticos para tratar trastornos respiratorios, composiciones farmacéuticas que los contienen, y procesos para su preparación. Reivindicación 1: Un método para el tratamiento de enfermedades o afecciones en donde la modulación de la actividad del receptor CRTh2 es beneficiosa, caracterizado porque comprende administrar a un paciente un compuesto de la fórmula (1), o una sal o solvato aceptables para uso farmacéutico del mismo, en donde: W es O, S(O), (donde n es 0, 1 ó 2), NR15, CR10R2 o CR1R2; X es hidrógeno, halógeno, ciano, nitro, S(O)2, R6, OR12 o C 1-6 alquilo que puede estar sustituido con uno o más átomos de halógeno; Y es hidrógeno, halógeno, CN, nitro, SO2R3, OR4, SR4, SOR3, SO2NR4R5, CONR4R5, NR4R5, NR6SO2R3, NR6CO2R6, NR6COR3, C2-6 alquenilo, C2-6 alquinilo, C3-7 cicloalquilo o C1-6 alquilo, donde los últimos cuatro grupos están opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre halógeno, OR6 y NR6R7, S(O)nR6 donde n es 0, 1 ó 2; Z es arilo o heteroarilo, opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre hidrógeno, halógeno, CN, OH, SH, nitro, CO2R6, SO2R9, OR9, SR9, SOR9, SO2NR10R11, CONR10R11, NR10R11, NHSO2R9, NR9SO2R9, NR6CO2R6, NHCOR9, NR9COR9, arilo, heteroarilo, C2-6 alquenilo, C2-6 alquinilo, C3-7 cicloalquilo o C1-6 alquilo, donde los últimos cuatro grupos están opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre halógeno, C3-7 cicloalquilo, OR6, NR6R7, S(O)nR6 (donde n es 0, 1 ó 2), CONR6R7, NR6COR7, SO2NR6R7 y NR6SO2R7; R1 y R2 representan en forma independiente un átomo de hidrógeno, halógeno, C2-6 alquenilo, C2-6 alquinilo, C3-7 cicloalquilo o un grupo C1-6 alquilo, donde los últimos cuatro grupos están opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre halógeno, C3-7 cicloalquilo, NR6R7, OR6, S(O)nR6 (donde n es 0, 1 ó 2); o R1 y R2 juntos pueden formar un anillo de entre 3 y 8 miembros que contiene opcionalmente uno o más átomos seleccionados entre O, S, NR6 y a su vez está opcionalmente sustituido con uno o más C1-3 alquilo o halógeno; R3 representa C3-7 cicloalquilo o C1-6 alquilo donde cualquiera de los dos pueden estar opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre halógeno, C3-7 cicloalquilo, OR6 y NR6R7, S(O)nR6 (donde n = 0, 1 ó 2), CONR6R7, NR6COR7, SONR6R7, y NR6SOR7; R4 y R5 representan en forma independiente hidrógeno, C3-7 cicloalquilo o C1-6 alquilo, donde los últimos dos grupos están opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre halógeno, C3-7 cicloalquilo, OR6 y NR6R7, S(O)nR6 (donde n = 0, 1 ó 2), CONR6R7, NR6COR7, SO2NR6R7 y NR6SOR7; o R4 y R5 junto con el átomo de nitrógeno al cual están unidos pueden formar un anillo heterocíclico saturado de entre 3 y 8 miembros que contiene opcionalmente uno o más átomos seleccionados entre O, S(O)n (donde n = 0, 1 ó 2), NR8, y a su vez está opcionalmente sustituido con halógeno o C1-3 alquilo; R6 y R7 representan en forma independiente un átomo de hidrógeno o C1-6 alquilo; R8 es hidrógeno, C1-4 alquilo, -CO(C1-4 alquilo), CO2(C1-4 alquilo), SO2R6 o CONR6(C1-4 alquilo); R9 representa arilo, heteroarilo, C3-7 cicloalquilo o C1-6 alquilo, donde los últimos dos grupos pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre halógeno, C3-7 cicloalquilo, arilo, heteroarilo, OR6 y NR6R7, S(O)nR6 (donde n = 0, 1 ó 2), CONR6R7, NR6COR7, SO2NR6R7, y NR6SO2R7; R10 y R11 representan en forma independiente arilo o heteroarilo, hidrógeno, C3-7 cicloalquilo o C1-6 alquilo, donde los últimos dos grupos están opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre halógeno, C3-7 cicloalquilo, arilo, heteroarilo, OR6 y NR6R7, S(O)nR6 (donde n = 0, 1 ó 2), CONR6R7, NR6COR7, SO2NR6R7 y NR6SO2R7; o R10 y R11 junto con el átomo de nitrógeno al cual están unidos pueden formar un anillo heterocíclico saturado de entre 3 y 8 miembros que contiene opcionalmente uno o más átomos seleccionados entre O, S(O)n (donde n = 0, 1 ó 2), Me, y a su vez está opcionalmente sustituidos con halógeno o C1-3 alquilo; R12 representa un átomo de hidrógeno o C1-6 alquilo que puede estar sustituido con uno o más átomos de halógeno; y R15 representa un átomo de hidrógeno, C1-6 alquilo, SO2R6 o COR6.
ARP040102990A 2003-08-21 2004-08-20 Derivados de acido fenoxiacetico AR045470A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302281A SE0302281D0 (sv) 2003-08-21 2003-08-21 Novel compounds
GB0412448A GB0412448D0 (en) 2004-06-04 2004-06-04 Novel compounds

Publications (1)

Publication Number Publication Date
AR045470A1 true AR045470A1 (es) 2005-10-26

Family

ID=34219638

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102990A AR045470A1 (es) 2003-08-21 2004-08-20 Derivados de acido fenoxiacetico

Country Status (29)

Country Link
US (2) US8003703B2 (es)
EP (1) EP1660431B1 (es)
JP (1) JP5025264B2 (es)
KR (1) KR101136175B1 (es)
AR (1) AR045470A1 (es)
AT (1) ATE427296T1 (es)
AU (1) AU2004266485B2 (es)
BR (1) BRPI0413490A (es)
CA (1) CA2535714C (es)
CO (1) CO5670367A2 (es)
CY (1) CY1110318T1 (es)
DE (1) DE602004020356D1 (es)
DK (1) DK1660431T3 (es)
ES (1) ES2322653T3 (es)
HK (1) HK1092777A1 (es)
HR (1) HRP20090280T1 (es)
IL (1) IL173522A (es)
IS (1) IS2693B (es)
MX (1) MXPA06001954A (es)
MY (1) MY142029A (es)
NZ (1) NZ545450A (es)
PL (1) PL1660431T3 (es)
PT (1) PT1660431E (es)
RU (1) RU2360901C2 (es)
SA (1) SA04250253B1 (es)
SI (1) SI1660431T1 (es)
TW (1) TWI347313B (es)
UY (1) UY28482A1 (es)
WO (1) WO2005018529A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
CN1930162B (zh) 2004-03-11 2010-06-16 埃科特莱茵药品有限公司 四氢吡啶并吲哚衍生物
EP2336113A1 (en) * 2004-05-29 2011-06-22 7TM Pharma A/S CRTH2 Receptor Ligands for Medical Use
EP1758571A1 (en) * 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for therapeutic use
GB0415320D0 (en) * 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
AR051966A1 (es) * 2004-11-23 2007-02-21 Astrazeneca Ab Derivados de acido fenoxiacetico utiles para el tratamiento de enfermedades respiratorias
GB0510585D0 (en) * 2005-05-24 2005-06-29 Novartis Ag Organic compounds
GB0510584D0 (en) * 2005-05-24 2005-06-29 Novartis Ag Organic compounds
US7858640B2 (en) * 2005-09-30 2010-12-28 Pulmagen Therapeutics (Asthma) Limited Quinolines and their therapeutic use
TW200745003A (en) * 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
GB0520324D0 (en) * 2005-10-06 2005-11-16 Astrazeneca Ab Novel compounds
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
WO2007052023A2 (en) * 2005-11-05 2007-05-10 Astrazeneca Ab Novel compounds
WO2007062678A1 (en) * 2005-11-29 2007-06-07 7Tm Pharma A/S Phenoxyacetic acid derivatives as crth2 receptor ligands
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
ATE545637T1 (de) 2005-12-15 2012-03-15 Astrazeneca Ab Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
US7741360B2 (en) 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
HUE030850T2 (en) 2006-06-16 2017-06-28 Univ Pennsylvania Prostaglandin D2 receptor antagonists for the treatment of hair loss
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
AU2008235282B2 (en) 2007-04-04 2011-02-24 Pulmagen Therapeutics (Asthma) Limited Quinolines and their therapeutic use
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
EP2213696B1 (en) * 2007-11-16 2016-10-19 Asahi Kasei Kabushiki Kaisha Polycarbonate diol
NZ585888A (en) 2007-12-14 2012-02-24 Pulmagen Therapeutics Asthma Ltd Indoles and their therapeutic use
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
GB0818365D0 (en) * 2008-10-07 2008-11-12 Argenta Discovery Ltd Quinoline compounds
CA2740863A1 (en) * 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Naphthylacetic acids
AU2010269668B2 (en) 2009-07-09 2013-12-19 Kyorin Pharmaceutical Co., Ltd. Diphenyl sulfide derivatives and medicines containing same as active ingredient
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
CA2805452C (en) 2010-07-05 2018-07-31 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
RU2014129613A (ru) 2011-12-21 2016-02-10 Актелион Фармасьютиклз Лтд Гетероциклильные производные и их применение в качестве модуляторов рецептора простагландина d2
EP2827952B1 (en) 2012-03-21 2021-07-07 The Trustees Of The University Of Pennsylvania Composition for stimulating hair growth
US9169270B2 (en) 2012-07-05 2015-10-27 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
AU2015242219A1 (en) 2014-03-29 2016-10-06 Lupin Limited Sulfonamide compounds as Voltage gated sodium channel modulators
EP4420734A2 (en) 2015-02-13 2024-08-28 Institut National de la Santé et de la Recherche Médicale Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
HUE051640T2 (hu) * 2015-05-27 2021-03-01 Jiangsu Hengrui Medicine Co Húgysav nátriumsó transzporter inhibitor és kristályos formája
WO2017019858A1 (en) 2015-07-30 2017-02-02 The Trustees Of The University Of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2
CN106831569B (zh) * 2015-12-07 2020-07-17 成都海创药业有限公司 喹啉类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途
GB201709396D0 (en) 2017-06-13 2017-07-26 Astrazeneca Ab Compounds for use as radioligands

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB690816A (en) 1950-01-02 1953-04-29 British Drug Houses Ltd Improvements in or relating to the manufacture of substituted phenoxy acetic acids
US3278524A (en) * 1962-03-13 1966-10-11 Beecham Group Ltd Penicillins and their production
CH432119A (de) * 1963-02-22 1967-03-15 Geigy Ag J R Verwendung von Halogen-o-hydroxy-diphenyläthern als antimikrobielle Mittel
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
DD113545A5 (es) 1973-03-30 1975-06-12
JPS5239888B2 (es) * 1973-05-28 1977-10-07
US3954852A (en) 1973-10-19 1976-05-04 Merck & Co., Inc. Indenylacetic acid compounds
ES431425A1 (es) * 1973-10-29 1977-01-16 Eisai Co Ltd Un procedimiento para la preparacion de derivados del acido 2-(m-fenoxifenil)-propionico.
CH582476A5 (es) * 1973-10-29 1976-12-15 Ciba Geigy Ag
GB1585963A (en) * 1976-10-14 1981-03-11 Lilly Industries Ltd Aryl sulphur compounds
US4248618A (en) * 1977-05-06 1981-02-03 Ici Australia Limited Derivatives of (pyrimidyloxy)phenoxy-alkanecarboxylic acid and herbicidal compositions thereof
DE2832435A1 (de) 1977-07-27 1979-02-08 Ciba Geigy Ag Phenoxy-phenoxy-alkancarbonsaeurederivate
FR2428629A1 (fr) * 1978-06-14 1980-01-11 Hexachimie Nouveaux composes bis(aryloxycarboxyliques), leur preparation et leur utilisation en therapeutique
JPS5951943B2 (ja) * 1978-08-21 1984-12-17 キツセイ薬品工業株式会社 新規なイミダゾ−ル誘導体
GB2041363B (en) 1979-01-19 1982-10-06 Pfizer Ltd N-benzyl-imidazoles
US4670566A (en) * 1979-07-12 1987-06-02 A. H. Robins Company, Incorporated 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4486593A (en) 1983-01-19 1984-12-04 The Upjohn Company 2-,3-, or 4-Pyridinylmethylamino arylic acids as thromboxane A2 synthetase and 5-lipoxygenase inhibitors
DE3419009A1 (de) * 1984-05-22 1985-11-28 Dr. Karl Thomae Gmbh, 7950 Biberach Neue substituierte bis(4-aminophenyl)sulfone, ihre herstellung und ihre verwendung als arzneimittel
US5006542A (en) * 1988-10-31 1991-04-09 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, derivatives thereof, compositions containing same and method of use
US5145790A (en) 1990-05-04 1992-09-08 Abbott Laboratories Reagents and method for detecting polychlorinated biphenyls
EP0540165A1 (en) 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
WO1993012086A1 (en) 1991-12-11 1993-06-24 Ss Pharmaceutical Co., Ltd. Arylamide derivative
CA2090283A1 (en) * 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
EP0607536B1 (en) * 1992-12-08 2001-01-24 Ss Pharmaceutical Co., Ltd. Arylamide derivatives
JPH06313995A (ja) 1993-04-28 1994-11-08 Hodogaya Chem Co Ltd 静電荷像現像用トナー
EP0622816B1 (en) 1993-04-30 1998-07-22 Kabushiki Kaisha Meidensha Electrode and process for forming an electrode material
JPH07140725A (ja) 1993-06-25 1995-06-02 Hodogaya Chem Co Ltd 負帯電性トナー用摩擦帯電付与部材
WO1997008126A1 (en) 1995-08-28 1997-03-06 American Home Products Corporation Phenoxy acetic acids as aldose reductase inhibitors and antihyperglycemic agents
DE19544828A1 (de) 1995-12-01 1997-06-05 Hoechst Ag Hochmolekulare Copolymere
JP2001505869A (ja) 1996-07-22 2001-05-08 モンサント カンパニー チオールスルホン メタロプロテアーゼ阻害剤
EP0839808A1 (en) 1996-10-29 1998-05-06 Novartis AG Pyrazole derivatives, processes for their preparation, and their use as herbicides
FR2763588B1 (fr) * 1997-05-23 1999-07-09 Cird Galderma Composes triaromatiques, compositions les contenant et utilisations
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US5942532A (en) 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
EP1012142B1 (en) 1997-09-12 2004-08-11 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
KR100340273B1 (ko) * 1997-10-14 2002-06-14 야마모토 카즈모토 비페닐-5-알칸산 유도체 및 이의 용도
ATE315230T1 (de) 1999-08-23 2006-02-15 Bml Inc Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
CA2400021A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
CA2405170A1 (en) 2000-04-24 2001-11-01 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
US7030123B2 (en) 2000-05-31 2006-04-18 Astrazeneca Ab Indole derivatives with vascular damaging activity
CN1245974C (zh) * 2000-06-28 2006-03-22 特瓦制药工业有限公司 卡维地洛
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
WO2002094770A2 (en) 2001-05-24 2002-11-28 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
CA2459515A1 (en) 2001-09-07 2003-03-20 Kazuhiko Torisu Indole derivatives
CN100378095C (zh) 2002-02-01 2008-04-02 弗·哈夫曼-拉罗切有限公司 作为α-1激动剂的取代吲哚
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003211427A1 (en) * 2002-02-18 2003-09-04 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
CA2479338A1 (en) * 2002-03-20 2003-10-02 Metabolex, Inc. Substituted phenylacetic acids
US7534897B2 (en) 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
WO2003097042A1 (fr) * 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Antagoniste de recepteur de pdg2
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
CN100406007C (zh) * 2002-12-20 2008-07-30 安姆根有限公司 哮喘和过敏性炎症调节剂
US7414063B2 (en) 2003-03-28 2008-08-19 Eli Lilly And Company Inhibitors of Akt (protein kinase B)
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
ES2257616T3 (es) * 2003-04-25 2006-08-01 Actimis Pharmaceuticals, Inc. Derivados del acido pirimidinilacetico utiles para el tratamiento de enfermedades mediadas por crth2.
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US7166738B2 (en) * 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
EP2336113A1 (en) 2004-05-29 2011-06-22 7TM Pharma A/S CRTH2 Receptor Ligands for Medical Use
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
AR051966A1 (es) 2004-11-23 2007-02-21 Astrazeneca Ab Derivados de acido fenoxiacetico utiles para el tratamiento de enfermedades respiratorias
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
WO2007052023A2 (en) 2005-11-05 2007-05-10 Astrazeneca Ab Novel compounds
ATE545637T1 (de) 2005-12-15 2012-03-15 Astrazeneca Ab Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
UA100983C2 (ru) * 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты

Also Published As

Publication number Publication date
RU2006107653A (ru) 2007-09-27
IS2693B (is) 2010-11-15
NZ545450A (en) 2009-04-30
EP1660431B1 (en) 2009-04-01
JP5025264B2 (ja) 2012-09-12
HRP20090280T1 (en) 2009-06-30
CA2535714A1 (en) 2005-03-03
IL173522A0 (en) 2006-07-05
KR20060064657A (ko) 2006-06-13
AU2004266485A1 (en) 2005-03-03
AU2004266485B2 (en) 2008-05-15
IS8350A (is) 2006-03-13
US8003703B2 (en) 2011-08-23
US20110281898A1 (en) 2011-11-17
CO5670367A2 (es) 2006-08-31
DE602004020356D1 (en) 2009-05-14
US20060293352A1 (en) 2006-12-28
MXPA06001954A (es) 2006-05-17
IL173522A (en) 2011-09-27
HK1092777A1 (en) 2007-02-16
MY142029A (en) 2010-08-16
TW200519075A (en) 2005-06-16
RU2360901C2 (ru) 2009-07-10
US8394986B2 (en) 2013-03-12
SA04250253B1 (ar) 2009-11-10
TWI347313B (en) 2011-08-21
UY28482A1 (es) 2005-03-31
EP1660431A2 (en) 2006-05-31
JP2007502806A (ja) 2007-02-15
KR101136175B1 (ko) 2012-04-17
SI1660431T1 (sl) 2009-08-31
PL1660431T3 (pl) 2009-07-31
ES2322653T3 (es) 2009-06-24
BRPI0413490A (pt) 2006-10-17
PT1660431E (pt) 2009-05-21
WO2005018529A3 (en) 2005-04-21
CY1110318T1 (el) 2015-01-14
CA2535714C (en) 2013-05-14
ATE427296T1 (de) 2009-04-15
DK1660431T3 (da) 2009-06-15
WO2005018529A2 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
AR045470A1 (es) Derivados de acido fenoxiacetico
AR043998A1 (es) Acidos fenoxiaceticos
AR051921A1 (es) Acidos sustituidos utiles como compuestos farmaceuticos para tratar trastornos respiratorios, composiciones farmaceuticas que los contienen, y procesos para su preparacion
AR055669A1 (es) Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
AR040498A1 (es) Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
AR056892A1 (es) Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
RU2007124329A (ru) ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ
AR069510A1 (es) Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10
AR043199A1 (es) Componentes heterociclicos utiles para el tratamiento de enfermedades inflamatorias y alergicas, proceso para su operacion y composicion farmaceutica que contiene dichos componentes
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
WO2009063202A3 (en) Use of crth2 antagonist compounds
AR058388A1 (es) DERIVADOS DE COMPUESTOS AROMATICOS SUSTITUIDOS uTILES PARA TRASTORNOS RESPIRATORIOS , COMPOSICIONES FARMACÉUTICAS Y PROCESOS PARA SU PREPARACIoN
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
AR045462A1 (es) DERIVADOS DE INDOLES SUSTITUIDOS eTILES COMO COMPUESTOS FARMACEUTICOS PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS
RU2008114378A (ru) Производные 2-аминопиримидина как модуляторы активности н4-рецептора гистамина
RU2008142600A (ru) Органическое соединение
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
AR060429A1 (es) Compuestos de tioxantina y composicion farmaceutica en base a dichos compuestos
RU2013108348A (ru) Конденсированные гетероарилы и их применение
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
AR077215A1 (es) Derivados de piperidina, composiciones farmaceuticas y metodos relacionados con ellos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal